Interim leukemia data show complete remission rates of 43% and 36% in two groups, versus 12% on placebo.
Moleculin Biotech (MBRX) reported interim Phase 2/3 trial data for Annamycin in relapsed/refractory AML, showing 43% and 36% remission rates vs. 12% on placebo. The study will continue, with results to be presented at the 2026 ASH Annual Meeting. If successful, it could support a New Drug Application submission.
How this was made
The 30-second read
Why it matters
The company’s first prespecified interim analysis reports complete remission rates of 43% and 36% in two Annamycin treatment groups versus 12% on placebo, and the independent Data Monitoring Committee recommended continuing the study without modification. This can improve perceived efficacy and reduce near-term trial execution risk, but it remains early-stage evidence with limited patient numbers and no detailed safety or durability metrics in the excerpt.
Market read
Traders may reprice MBRX based on early efficacy signals and a DSMC continuation decision, while still discounting for interim-only evidence and ongoing financing needs.
What to watch
The release does not provide safety details, duration of response, or statistical significance; financing risk is also highlighted as a potential constraint on trial execution.
Background
Moleculin Biotech is running the MIRACLE (MB-108) pivotal Phase 2/3 trial of Annamycin (naxtarubicin) plus cytarabine (Ara-C) in relapsed or refractory AML, following earlier MB-106 Phase 1/2 work.
Ticker impact
Moleculin (MBRX) reported first prespecified interim analysis from its MB-108 Phase 2/3 trial, including complete remission rates in Annamycin arms vs placebo.
Likely upward bias as traders price improved clinical efficacy and reduced near-term trial risk ahead of the next interim analysis.
The release discloses early efficacy signals (complete remission rates) and a continuation decision, both of which can shift probability-weighted outcomes for a clinical-stage biotech. However, it is still interim data from a limited sample (first 45 randomized patients), so follow-through depends on later interim and final results.
Market effects
Positive interim AML efficacy read-through can lift sentiment for anthracycline and AML trial pipelines, but impact is likely contained to small-cap biotech risk appetite.
Primarily US biotech sentiment; limited direct regional spillover beyond healthcare/biotech trading desks.
ASH meeting-related visibility may attract international biotech investors, but the core catalyst is company-specific interim trial data.
Counterpoint
Early complete remission rates may not translate into durable survival or overall response, and interim analyses can be noisy with small patient counts.
Key entities
- companyMoleculin Biotech, Inc.
Nasdaq-listed clinical-stage biotech advancing Annamycin (naxtarubicin) in AML via the MB-108 pivotal Phase 2/3 trial.
- drug_candidateAnnamycin (naxtarubicin)
Lead drug candidate evaluated in combination with cytarabine (Ara-C) for relapsed or refractory AML.
- clinical_trialMB-108 (MIRACLE Trial)
Pivotal, adaptive, randomized, double-blind, placebo-controlled Phase 2/3 trial in relapsed or refractory AML.
- eventASH 2026 Annual Meeting
Conference where the abstract with interim data is accepted for poster presentation in December 2026.
